The Life Sciences Strategy Summit on IP and Exclusivity on October 13-15, 2025 in Unterschleissheim, Germany

The Life Sciences Strategy Summit on IP and Exclusivity is a premier annual event convening pharmaceutical, biotech, and legal professionals to explore the evolving landscape of intellectual property and regulatory exclusivity. Scheduled for October 2025 in Munich, Germany, the summit offers a platform for in-depth discussions on patent strategies, regulatory frameworks, and market exclusivity challenges.

Attendees can anticipate sessions on the latest developments in Supplementary Protection Certificates (SPCs), including the implications of recent CJEU decisions and the SPC waiver's impact on both generic and innovator strategies. The conference will also delve into the intersection of regulatory and IP law, with topics covering clinical trials, data exclusivity, and the Pharmaceutical Strategy for Europe. Additionally, panels will address patentability requirements within the life sciences industry, focusing on patent quality, the G2/21 decision, enablement, and the role of the Patent Trial and Appeal Board (PTAB). The influence of the Unified Patent Court (UPC) on life science strategies will also be a key discussion point, featuring industry-led sessions and a judges panel .

Preceding the main summit, the SPC AND PTE Forum offers a focused day on October 8, 2025, dedicated to SPC strategies, including updates on litigation, the Unitary SPC proposal, and foundational knowledge essential for patent practitioners .

With over 65 speakers and participants from more than 26 countries, the summit provides unparalleled networking opportunities and insights into shaping robust IP and regulatory strategies for the future .

URLs:

Tickets: https://go.evvnt.com/3007159-0?pid=10008

Brochure: https://go.evvnt.com/3007159-3?pid=10008

Sponsor: https://go.evvnt.com/3007159-4?pid=10008

Website: https://go.evvnt.com/3007159-5?pid=10008

Time: 8:00 AM - 6:00 PM

Prices:

Tier 1 - In-House Counsels: EUR 499.00,

Tier 2 - All Other (2 Day Conference Pass): EUR 1399.00,

Tier 2 - All Other (3 Day Conference Pass): EUR 1799.00,

One Day Pass: EUR 999.00

Speakers: Julia Pike, Global Head of IP, Sandoz, Toni Santamaria, SVP – IP and Legal, Adalvo, James Horgan, Chief IP Counsel, MSD, Nicolas Ruiz, Head of IP, Esteve, Tamaris Bucher, Principal Patent Counsel, Novartis, Natalia Wright, Associate General Patent Counsel, UCB, Andreas Robinson, Senior IP Counsel, Amgen, Dorian Immler, Head of Patents- Pharma, Bayer, Ana Gabarda, Director- Corporate Patent Counsel, Merck, Oliver Werner, Head of SPC Working Group, German Patent and Trade Mark Office, Ana Gabarda, Director- Corporate Patent Counsel, Merck, Ana Lopez Lozano, Lead Patent Counsel, Zentiva, Andre Andrade, RWS, Andreas Robinson, Senior IP Counsel, Amgen, Axel Korth, Associate General Counsel, Shionogi, Bianca Vos, Partner, Hoffmann Eitle, Christina Thomson, Managing Associate, Simmons and Simmons, Corinna Sundermann, Senior VP IP, Fresenius Kabi, Deborah Sterling, Director, Sterne Kessler, Dorian Immler, Head of Patents- Pharma, Bayer, Eduardo Hallak, Founding Partner, Licks Attorneys, Eva Ehlich, Partner, Maiwald, Fergal Brady, Patent Examiner, Irish IPO, Frank Landolt, Chief IP Counsel and Legal, Confo Therapeutics, Ha Kung Wong, Partner, Venable, Hannes Iserentant, Head of IP, Celyad Oncology, Heli Pihlajamaa, Principal Director, EPO, Ina Bürck, Senior IP Counsel, Amgen, James Horgan, Chief IP Counsel- Policy and Litigation, MSD, Jorge Goldstein, Partner, Sterne Kessler, Julia Pike, Global Head of IP, Sandoz, Karin Pramberger, Head of IP, Polpharma Group, Katherine Helm, Partner, Dechert, Margaret O’Gara, Head of IP- NanoBiotix, Martijn de Lange, Patent Examiner, Dutch Patent Office, Martin Schmidt, Technically Qualified Judge, UPC, Mathilde Rauline, Head of Greater Europe Patent Litigation, Sanofi, Michael Peers, Partner, Potter Clarkson, Michal Porubsky, Associate General Counsel, Novo Nordisk, Natalia Wright, Associate General Patent Counsel, UCB, Nicolas Ruiz, Head of IP, Esteve, Oliver Werner, Head of SPC Working Group, German Patent and Trade Mark Office, Patrick Purcell, Senior Patent Examiner, UK IPO, Rob Cerwinski, Partner, Gemini Law, Rob Rodrigues, Partner, NSN Law, Roberto Romandini, Technically Qualified Judge, UPC, Robin Ellis, Partner, Reddie and Grose, Sharada Devarasetty, Senior Director IP, GH Research, Stefanie Kies, Senior Director IP, Polpharma Biologics, Tamaris Bucher, Principal Patent Counsel, Novartis, Toni Santamaria, Senior Vice President Intellectual Property and Legal, Adalvo, Viviane Kunisawa, Head of Patent Litigation and Regulatory Law for Life Sciences and Agribusiness, Daniel Law